A new study conducted by researchers at Suleyman Demirel University in Türkiye has found that cannabidiol (CBD), a compound derived from cannabis, may significantly enhance the effectiveness of the chemotherapy drug etoposide in treating prostate cancer.
Published in the US National Library of Medicine, the study suggests that CBD could play a vital role in improving therapeutic outcomes for patients with this common cancer.
The study focused on the effects of combining CBD with etoposide on prostate cancer cells, specifically evaluating the impact on cell growth, survival, and various cancer-related signaling pathways. The researchers found that “CBD strongly enhanced the etoposide-mediated suppression” of key factors involved in cancer progression, including androgenic signaling, angiogenic factors, and the proto-oncogene c-Myc.
Continue reading